Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Encysive Thelin Approval Could Come Days Ahead Of Gilead’s Ambrisentan

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s regulatory timeline for reviewing the two pulmonary arterial hypertension medications may fall neck and neck.

You may also be interested in...

Actelion Will Take Novel Sleep Therapy Into Phase III This Year

The Swiss company, known for its pulmonary hypertension dominance, welcomes awareness-raising competition from new entrants like Gilead, CFO Oakley says.

Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial

Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.

Gilead Letairis Will Be Available Through LEAP Restricted Distribution Program

Ambrisentan beats out Encysive's Thelin in race for FDA approval for treatment of pulmonary arterial hypertension.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts